外周血HBV_cccDNA检测在乙型肝炎患者抗病毒治疗中的应用

目的:研究外周血cccDNA在乙肝患者抗病毒治疗中的作用。方法:在34例乙型肝炎患者抗病毒治疗前、6个月和12个月采集外周血,分别检测血浆ALT、AST、cccDNA、HBV-DNA和单个核细胞的cccD-NA,进行统计学分析。结果:ALT、AST水平在抗病毒治疗前与治疗6个月、12个月均有差别(P<0.01),但治疗12个月与6个月无差别(P分别为0.36、0.28);血浆cccDNA与HBV-DNA治疗前、治疗6个月与12个月三组间均有差别(P<0.01);按治疗前血浆cccDNA阴、阳性分组,治疗6个月后HBV-DNA转阴率有差别(P=0.048<0.05),治疗12个月后HBV-DNA转阴率无差别(P=0.667)。结论:外周血血浆cccD-NA检测对抗病毒治疗有一定预测意义。外周血单个核细胞cccDNA的检测对于肝移植患者乙肝的复发提供了理论依据。

Application of peripheral blood HBV cccDNA detection in antiviral treatment of patients with Hepatitis B

Objective:To study peripheral blood cccDNA use in antiviral therapy for hepatitis B sufferers.Methods:Peripheral blood samples from 34 hepatitis B patients were collected before treatment,6 months and 12 months after treatment,then plasma ALT,AST,cccDNA,HBV-DNA and mononuclear cccDNA were statistically analyzed.Results:Levels of ALT and AST before antiviral treatment had differences with those of 6 months and 12 months after treatment(P<0.01),but no difference was found between 12 months and 6 months after treatment(P values were 0.36 and 0.28 respectively).Plasma cccDNA and HBV-DNA had differences among levels before antiviral treatment,6 months and 12 months after treatment(P<0.01).According to the plasma cccDNA negative and positive before treatment,the samples were grouped.HBV-DNA negative-converting rate changed significantly after treatment for 6 months(P=0.048<0.05),while HBV-DNA negative-converting rate changed little after treatment for 12 months(P=0.067).Conclusion:Peripheral blood cccDNA detection had certain significance in prediction of antiviral therapy,and detection of mononuclear cccDNA in peripheral blood can provide theoretical basis for recurrence of hepatitis B in liver transplant patients.